Drug Profile

Ludaterone acetate - ASKA Pharmaceutical

Alternative Names: AKP-009

Latest Information Update: 09 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

31 Jul 2025 Kyorin Pharmaceutical terminates its licence agreement for AKP 009 with ASKA Pharmaceuticals (Kyorin Pharmaceutical pipeline, October 2025)
30 Nov 2022 Ludaterone acetate is still in phase IIa trial for benign prostate hyperplasia in Japan (ASKA Pharmaceutical pipeline, November 2022) (JapicCTI-195084)
29 Sep 2022 ASKA Pharmaceutical completes a phase II trial in Benign prostatic hyperplasia in Japan (PO) prior to September 2022 ((JapicCTI-195084) (ASKA Pharmaceutical pipeline, September 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com